Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  You, Joyce H S ^a   Ming, Wai Kit ^a   Chan, Paul K S ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Cost effectiveness analysis; Elderly; Hong Kong; Quadrivalent influenza vaccine; Trivalent influenza vaccine

Indexed keywords

INFLUENZA VACCINE; QUADRIVALENT INFLUENZA VACCINE; TRIVALENT INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HONG KONG; HOSPITAL ADMISSION; HUMAN; INFLUENZA B; QUALITY ADJUSTED LIFE YEAR; VERY ELDERLY; COMPARATIVE STUDY; ECONOMICS; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HOSPITALIZATION; IMMUNOLOGY; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; SEASON; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; COST-BENEFIT ANALYSIS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HONG KONG; HOSPITALIZATION; HUMANS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; SEASONS;

EID: 84965188416     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-014-0618-9     Document Type: Article

References (31)

1. Chan PK, Chan MC, Cheung JL, Lee N, Leung TF, Yeung ACM, Wong MCS, Ngai KLK, Nelson EAS, Hui DSC: Influenza B lineage circulation and hospitalization rates in a subtropical city, Hong Kong, 2000-2010. Clin Infect Dis 2013, 56:677-684.
2. Reed C, Meltzer MI, Finelli L, Fiore A: Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30:1993-1998.
3. Lee BY, Bartsch SM, Willig AM: The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012, 30:7443-7446.
4. Lee N, Chan PKS, Lui GCY, Wong BCK, Sin WWY, Choi KW, Wong RYK, Lee ELY, Yeung ACM, Ngai KLK, Chan MCW, Lai RWM, Yu AWY, Hui DSC: Complications and outcomes of pandemic 2009 influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis 2011, 203:1739-1747.
5. Chowell G, Miller MA, Viboud C: Seasonal influenza in the United States, France, and Australia: transmission and prospects for control. Epidemiol Infect 2008, 136:852-864.
6. Centers for Disease Control and Prevention: Updated adjusted estimates of 2012-2013 seasonal influenza vaccine effectiveness in the United States. Assessed on 30 April 2014: http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-jun13.pdf
7. Centers for Disease Control and Prevention: Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine-Marshfield, Wisconsin, 2007-08 influenza season. MMWR Morb Mortal Wkly Rep 2008, 57:393-398.
8. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK, Marshfield Influenza Study Group: Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009, 199:159-167.
9. Coleman LA, Kieke B, Irving S, Shay DK, Vandermause M, Lindstrom S, Belongia EA: Comparison of influenza vaccine effectiveness using different methods of case detection: clinician-ordered rapid antigen tests vs. active surveillance and testing with real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Vaccine 2011, 29:387-390.
10. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S: Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010, 51:997-1004.
11. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC: Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361:1260-1267.
12. Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, Newton DW, Campbell SA, Boulton ML, Monto AS: Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis 2008, 198:312-317.
13. Talbot HK, Griffin MR, Chen Q, Zhu Y, Williams JV, Edwards KM: Effectiveness of seasonal vaccine in preventing confirmed influenzaassociated hospitalizations in community dwelling older adults. J Infect Dis 2011, 203:500-508.
14. Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, Petrie JG, Lofthus G, Meece JK, Williams JV, Berman L, Breese Hall C, Monto AS, Griffin MR, Belongia E, Shay DK, US Flu-VE Network: Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012, 55:951-959.
15. Chan D: Seasonal influenza vaccination coverage survey for the 2012/2013 season. Communicable Diseases Watch 2013, 10:74-77.
16. Smith KJ, Roberts MS: Cost-effectiveness of newer treatment strategies for influenza. Am J Med 2002, 113:300-307.
17. Sander B, Hayden FG, Gyldmark M, Garrison LPJ: Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. Pharmacoeconomics 2006, 24:373-386.
18. Talbird SE, Brogan AJ, Winiarski AP, Sander B: Cost-effectiveness of treating influenza-like illness with oseltamivir in the United States. Am J Health-Syst Pharm 2009, 66:469-480.
19. Mauskopf JA, Cates SC, Griffin AD, Neighbors DM, Lamb SC, Rutherford C: Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics 2000, 17:611-620.
20. Tengs TO, Wallace A: One thousand health-related quality-of-life estimates. Med Care 2000, 38:583-637.
21. Sackett DL, Torrance GW: The utility of different health states as perceived by the general public. J Chronic Dis 1978, 31:697-704.
22. Rothberg MB, He S, Rose DN: Management of influenza symptoms in healthy adults. J Gen Intern Med 2003, 18:808-815.
23. Petrie JG, Ohmit SE, Hohnson E, Cross RT, Monto AS: Efficacy studies of influenza vaccines: Effect of end points used and characteristics of vaccine failures. J Infect Dis 2011, 203:1309-1315.
24. Census and Statistics Department, The Government of Hong Kong SAR. Assessed on 24 October 2013: www.censtatd.gov.hk/
25. Gold MR, Franks P, McCoy KI, Fryback DG: Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998, 36:778-792.
26. Fees and Charges, Hospital Authority, Hong Kong. Assessed on 7 October 2013: www.ha.org.hk
27. Cost-effectiveness thresholds. World Health Organization. Assessed on 3 December 2013: www.who.int/choice/costs/CER_thresholds/en/index.html
28. You JHS, Wong WCW, Ip M, Lee NLS, Ho SC: Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities. J Epidemiol Community Health 2009, 63:906-911.
29. Wu P, Goldstein E, Ho LM, Yang L, Nishiura H, Wu JT, Ip DK, Chuang SK, Tsang T, Cowling BJ: Excess mortality associated with influenza A and B virus in Hong Kong, 1998-2009. J Infect Dis 2012, 206:1862-1871.
30. Goldstein E, Vibound C, Charu V, Lipsitch M: Improving the estimation of influenza-related mortality over a seasonal baseline. Epidemiology 2012, 23:829-838.
31. Kwong EW, Lam IO: Chinese older people in Hong Kong: health beliefs about influenza vaccination. Nursing Older People 2008, 20:29-33.